ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is an protein complex 1 (PC1) inhibitor that targets the OXPHOS pathway in mitochondria and decreases the energy supply of resistant cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with good tolerability and ImmunoMet anticipates initiating Phase 2 PoC ...
ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is an protein complex 1 (PC1) inhibitor that targets the OXPHOS pathway in mitochondria and decreases the energy supply of resistant cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with good tolerability and ImmunoMet anticipates initiating Phase 2 PoC studies in oncology next year.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.